61093-69-4

Basic information

• Product Name: 1,3,2',6',3''-pentakis(N-benzyloxycarbonyl)-3'-deoxykanamycin B
• Synonyms: 1,3,2',6',3''-pentakis(N-benzyloxycarbonyl)-3'-deoxykanamycin B
• CAS NO: 61093-69-4
• Molecular Weight: 1138.19
• Mol File: 61093-69-4.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 1,3,2',6',3''-pentakis(N-benzyloxycarbonyl)-3'-deoxykanamycin B(CAS DataBase Reference)
• NIST Chemistry Reference: 1,3,2',6',3''-pentakis(N-benzyloxycarbonyl)-3'-deoxykanamycin B(61093-69-4)
• EPA Substance Registry System: 1,3,2',6',3''-pentakis(N-benzyloxycarbonyl)-3'-deoxykanamycin B(61093-69-4)

Safety Data

• Hazardous Substances Data: 61093-69-4(Hazardous Substances Data)

Upstream product

• 32986-56-4 tobramycin 
• 501-53-1 benzyl chloroformate 
• 49842-07-1 tobramycin sulfate 

Downstream Products

• 142859-95-8 1,3,2',6',3''-pentakis(N-benzyloxycarbonyl)-5,3'-dideoxy-5,5-difluorokanamycin B 
• 142859-72-1 5,3'-dideoxy-5,5-difluorokanamycin B 
• 142906-20-5 4',2'',4'',6''-tetra-O-acetyl-1,3,2',6',3''-pentakis(N-benzyloxycarbonyl)-5,3'-dideoxy-5-oxokanamycin B 
• 142859-94-7 4',2'',4'',6''-tetra-O-acetyl-1,3,2',6',3''-pentakis(N-benzyloxycarbonyl)-5,3'-dideoxy-5,5-difluorokanamycin B 
• 204136-38-9 C₅₈H₆₆N₈O₁₈ 
• 533903-21-8 C₆₈H₇₉N₅O₂₄ 
• 533903-17-2 acetic acid 5-acetoxy-2-{3-[5-acetoxy-3-benzyloxycarbonylamino-6-(benzyloxycarbonylamino-methyl)-tetrahydro-pyran-2-yloxy]-2-allyloxy-4,6-bis-benzyloxycarbonylamino-cyclohexyloxy}-6-acetoxymethyl-4-benzyloxycarbonylamino-tetrahydro-pyran-3-yl ester 
• 533903-18-3 C₆₈H₇₇N₅O₂₄ 
• 194785-91-6 C₆₅H₇₃N₅O₂₁S 
• 142859-93-6 4',2'',4'',6''-tetra-O-acetyl-1,3,2',6',3''-pentakis(N-benzyloxycarbonyl)-3'-deoxykanamycin B 

Relevant articles and documents

Tobramycin analogues with C-5 aminoalkyl ether chains intended to mimic rings III and IV of paromomycin

Based on available X-ray structural and modeling data, a series of tobramycin derivatives with C-5 ether chains bearing basic groups were synthesized. These were intended to be hybrid molecules that combine features of tobramycin and paromomycin. Their binding to ribosomes and their antibacterial activity were determined. The 5-O-(2-guanidylethyl) ether of tobramycin (9g) was the most active analogue in the series.

Dimeric aminoglycosides: Design, synthesis and RNA binding

The design and synthesis of symmetrical and non-symmetrical dimeric aminoglycosides derived from kanamycin A, tobramycin, and neomycin B are described. The covalently-linked dimeric aminoglycosides show enhanced activity as ribozyme inhibitors when compared to their natural counterparts.